Simlandi and Flu Vaccine Compatibility
Patients receiving Simlandi (adalimumab-ryvk) can and should receive the influenza vaccine safely, using inactivated influenza vaccine (IIV) formulations only—live attenuated influenza vaccine (LAIV) is contraindicated.
Vaccine Safety and Compatibility
Adalimumab is a TNF-alpha inhibitor that causes immunosuppression, placing patients at higher risk for influenza complications 1, 2. The inactivated influenza vaccine is both safe and effective in patients on adalimumab 3. A landmark study demonstrated that patients with rheumatoid arthritis receiving adalimumab achieved protective antibody titers in 98% of cases following influenza vaccination, with similar response rates to placebo-treated patients (94.5%) 3.
Which Vaccine Formulation to Use
Use only inactivated influenza vaccine (IIV4 or IIV3)—never live attenuated influenza vaccine (LAIV).
The rationale is clear:
- LAIV is absolutely contraindicated in immunosuppressed patients, including those on biologics like adalimumab 2, 4
- IIV formulations (quadrivalent or trivalent) are safe and appropriate 5, 6
- Standard intramuscular administration at 0.5 mL per dose for adults 5
Timing Considerations
Administer the influenza vaccine on schedule without holding adalimumab. Recent rheumatology guidelines specifically address this:
- Continue adalimumab without interruption for influenza vaccination 7
- Do not delay vaccination waiting to time it with adalimumab dosing 7
- Optimal vaccination timing is mid-October through mid-November 1
This differs from other vaccines (like pneumococcal) where timing around adalimumab doses may matter, but for influenza, the seasonal nature makes on-schedule vaccination the priority 7.
Clinical Benefits
The benefits of vaccination are substantial and outweigh theoretical concerns about reduced immunogenicity:
- Influenza-related adverse events occurred in only 5% of vaccinated adalimumab patients versus 14% in unvaccinated patients 8
- Long-term safety data from 15,132 patients confirms no additional safety risks from vaccination 8
- Patients on adalimumab remain at high risk for influenza complications, making vaccination critical 9
Important Caveats
Egg allergy screening is required before any influenza vaccination. All IIV formulations except cell culture-based vaccines contain egg protein 5, 10. For patients with severe egg allergy (anaphylaxis), either:
- Use cell culture-based IIV4 (Flucelvax Quadrivalent), which is egg-free 5
- Refer to an allergist for supervised vaccination 10
Do not use LAIV under any circumstances in immunosuppressed patients—this includes the intranasal FluMist formulation 2, 4.
Concurrent Medications
Influenza vaccine can be administered simultaneously with other inactivated vaccines at different injection sites 1, 10. There are no contraindications to giving pneumococcal vaccine at the same visit 1.